Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hy
Go back to Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hy| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.57 +3.28 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.29 | 52 Week High | $58.46 | |||
| Open | $161.17 | 52 Week Low | $31.25 | |||
| Day High | $161.79 | P/E | N/A | |||
| Day Low | $159.32 | EPS | $-0.69 | |||
| Volume | 718,929 | |||||
